RESEARCH ARTICLE

MALE RHEUMATOID ARTHRITIS IN ALL MOROCCAN RA UNDERGOING BIOThERAPY: PREVALENCE, CHARACTERISTICS, AND RESPONSE TO BIOLOGICAL TREATMENTS (NATIONAL REGISTRY)

Abdelhafid Guich¹, Fatimazahra Haddani¹, El Mehd Boudhar¹, Soumia Oulahrir¹, Tarik Youssoufi¹, Redouane Abouqal¹, Lahcen Achemlal³, Fadoua Allali³, Rachid Bahiri³, Imane El Bouchti⁶, Abdellah El Maghraoui⁷, Imad Ghozlanî⁸, Taoufik Harzy⁹, Ihsane Hmamouchi²,¹⁰, Linda Ichchou¹¹, Oufa Mkinsi¹², Redouane Niamane¹³ and Hasna Hassikou¹

1. Rheumatology Department, Meknes Military Hospital, Hassan II University Hospital, Morocco.
2. Laboratory of Biostatistics, Clinical and Epidemiological Research (LBRCE); Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco.
3. Rheumatology Department, Mohamed V Military Hospital, Ibn Sina university center, Rabat, Morocco.
4. Rheumatology Department B, El Ayachi Hospital, Rabat-Salé Teaching Hospital, Morocco.
5. Rheumatology Department A, El Ayachi Hospital, Rabat-Salé Teaching Hospital, Morocco.
6. Rheumatology Department, Arrazi Hospital, Mohammed VI university hospital, Marrakech, Morocco.
7. Cabinet of Rheumatology, Rabat, Morocco.
8. Rheumatology Department, Agadir Teaching Hospital, Morocco.
9. Rheumatology Department, Hassan II university hospital Fez, Morocco.
10. Skhirat-Temara Provincial Hospital, Morocco.
11. Rheumatology Department, Mohammed VI Oujda University Hospital, Morocco.
12. Rheumatology Department, Ibn Rochd university hospital, Casablanca, Morocco.
13. Rheumatology Department, Avicenne Military Hospital, Mohammed VI university hospital Marrakech, Morocco.

Manuscript Info

Manuscript History
Received: 25 March 2021
Final Accepted: 29 April 2021
Published: May 2021

Key words:- Rheumatoid Arthritis, Gender, Biotherapy

Abstract

Introduction: This study aims at reporting the RA male frequency while undergoing biotherapy and describing the epidemiological characteristics (clinical, biological and radiological) in relation to female RA. It also evaluates its impact on the response to biological treatments.

Materials and methods: There are 224 patients followed for rheumatoid arthritis, responding to ACR/EULAR 2010 criteria during their biotherapy. They were included in the national "RBSMR" registry. The patients were divided into two groups and were compared at the basis of their gender in terms of the socio-demographic, clinical, biological, radiological parameters, and response to the treatment.

Results: The average age of the patients under study is 51.94 ans±11.36 years old [20-80]. The presence of male rheumatoid arthritis under biotherapy is 12.4%. The mean age of RA male is 55.96±9 years old. The estimated duration of progression of male RA is 542 weeks with an average diagnostic deadline of 562.61 weeks. As a description of the case study, 28.6% of men are diagnosed with comorbidities (mainly tuberculosis 21.4%) while 10.7% of men are smokers. There is an average sedimentation rate (1st hour) at 52.6mm.
Rheumatoid serology is found to be positive in 96.4% of cases. Radiological abnormalities are observed in 90.5% of the cases. Male rheumatoid arthritis is related to a shorter duration of progression (542 versus 768 weeks in females, p=0.01), liberal profession (p=0.00), study level (p=0.003), duration between diagnosis and the starting of biotherapy (p=0.021), EVA pain patient and physician (p=0.003, p=0.01) Tobacco (p=0.006), and pulmonary tuberculosis (p=0.029). On the other hand, it was not associated with the following parameters: age, duration of diagnosis, disease intensity, rheumatoid serology, structural damage nor with the DAS 28vs response during one year.

Conclusion: The male RA rate in RBSMR study is 12.4% in that there is no significant difference between the sexes in clinical presentation, disease activity, disease severity, rheumatoid serology and response to the biotherapy. However, male RA was related to smoking, liberal profession, and history or occurrence of pulmonary tuberculosis.

Copy Right, IJAR, 2021. All rights reserved.

Introduction:
Rheumatoid arthritis (RA) is the most commonly known chronic inflammatory rheumatic disease, affecting women four times more than men (From 35 to 55 years old). Historically speaking, researches have already shown interest in studying this disease in relation to the issue of gender. In fact, various published works come to the conclusion that there is difference between the two sexes while being diagnosed with RA in terms of prevalence, age at the beginning of the disease and auto-antibody positivity [1]. Similarly, the evolution of female RA is severe compared to male RA.

Practically speaking, rheumatologists do not pay much attention to the patients' gender. However, scientific development proves to be unexpected. Hence, male sex has been shown as major predictor factor of remission in early RA [2,3]. Some studies suggest that males respond positively to the biological treatment in comparison to females [4–6].

In this study, we want, mainly, to report the male RA prevalence while undergoing a biological treatment (refractory to CsDMARDS) through describing its clinical and paraclinical profile and comparing it to the female RA. Then, we compare how both males and females respond to the biological treatment.

Materials And Methods:
This is a multi-center group study that includes 10 rheumatology departments in university hospitals in Morocco: Agadir, Casablanca, Fez, Marrakech, Meknes, Rabat, Sale and Oujda.

The sponsor is the Moroccan Society of Rheumatology (SMR). This study involves 224 patients who are older than 18 years of age, treated from RA, meeting ACR/EULAR 2010 criteria on biotherapy (or who have received an infusion of rituximab within the last 12 months.) These patients are included in the national database that is closed at the end of January 2019. And a second database from this registry includes biologic response data after 6 and 12 months of inclusion, "RBSMR study" data frozen at one year.

The first step we followed, is that we reported the male RA prevalence within the RA population included in the national biotherapy database. After that, we divided the patients into two groups: Male and female RA patients in order to compare their socio-economic, epidemiological, clinical, biological, radiological, and disease severity characteristics. However, the disease evolution and the patients’ response to the treatment were not analyzed because the patients were in the first phase of inclusion.

The second step revolved around comparing the patients’ response to the biological treatment in male and female RA using the primary criterion of judgment: DAS28VS and the secondary criterion: EVA pain, EVA fatigue, joint index, synovial index, and CRP (the absence of inflammatory syndrome was judged on a CRP less than or equal to 6mg/l).
Using SPSS (Statistical Package for the Social Sciences) version 13 software, a comprehensive description of the population under study (frequencies and means plus standard deviation) is given. A bi- and multi-varied analysis was conducted using statistical tests (the chi-square test, the Student's T-test for independent sample and a multi-varied logistic regression test), comparing the characteristics of male versus female RA patients. The significant threshold was set at \( p<0.05 \).

**Results:**

The average age of the population of 224 RA patients was 51.94±11.36 years old [20-80], divided into 28 men and 196 women. The average age of male RA patients was 55.96±9 years old while that of female RA patients was 51.37±11 years old. The prevalence of male RA was 12.5% (versus 87.4% female RA).

The characteristics of the population under study is as follows. 85.72% of men were married compared to 70.1% of women. Also, 35.7% of the men were illiterate compared to 48.2% of women. For work, 60% of men had a liberal profession: commerce, handicraft, etc. (compared to 2% of the women) while 83.2% of the women were housewives. For health services, 50% of the men had FAR social security coverage and 35.7% had RAMED social assistance, while 30% of the women had FAR health insurance and 43.1% had RAMED. The average PR duration progress for males was 542 weeks in comparison to 768 weeks for females, with an average diagnostic period of 562.61 weeks for men versus 767.19 weeks for women. Comorbidities were observed in 28.6% of men versus 36.0% of women. After one year of biological treatment, 3.6% of men had experienced a new comorbidity compared to 13.8% of women. One of the most common comorbidities for men is tuberculosis (21.4% versus 7.4% for women). 10.7% of men were smokers versus 0.5% of women. We found an average sedimentation rate of 52.6mm during the first hour for men versus 40.3mm for women. Rheumatoid serology (rheumatoid factor and/or ACPA) was positive in 96.4% of males RA versus 94.1% of females RA. The average DAS 28 (CRP) was 4.06 versus 3.51 for women. Mean HAQ was 1.17 for men versus 1.23 for women. Radiological abnormalities were observed in 90.5% of cases versus 92.8% for RA females. The use of orthopedic surgery (arthrodesis and joint replacements including MCP/MTP) was noticed in 3.6% of male RA patients versus 7.1% of female ones. (Table 1).

53.8% of men had a DAS 28 VS that is superior than 3.2 versus 68.27% of women. After one-year treatment, 65% of male RA patients showed good results (remission or low disease activity (LDA)) according to the primary outcome of our study (DAS28 vs.) versus 52.21% of women. EULAR response (delta DAS28VS. between admission and 12-month visit) 55.55% of men were responsive or had a moderate response vs. 58.95% of women. The CRP was high in 62.29% of men versus 65.64% of women. After 12 months of biologic treatment, 56.52% of male RA patients had a positive CRP response versus 53.69% of women. A biologic treatment maintenance rate is 81.2% in men versus 86.7% in women. 3.6% of men had developed side-effects to biologic treatments versus 13.8% of women (\( p=0.1 \)). (figure 1)

According to the bivariate analysis, the male RA disease is associated to an evolutionary duration that is less important (\( p=0.01 \), liberal profession (\( p=0.00 \)), low educational level (\( p=0.003 \)), short duration between diagnosis and the starting of biotherapy (\( p=0.021 \)), extensive patient-physician pain EVA (\( p=0.003, p=0.01 \)), smoking (\( p=0.006 \)), and the occurrence of pulmonary tuberculosis during biotherapy (\( p=0.029 \)), but was not associated with age, diagnosis duration, and structural abnormality (Table 2). Multivariate regression analysis mentioned that there is a relation between male RA and the following criteria: smoking, occupation, and the appearance or history of pulmonary tuberculosis.

In our study, the bivariate statistical analysis did not reveal that responding to the treatment is affected by the male impact for either the primary criterion: DAS 28 VS (\( p=0.455 \)), or the secondary ones: EULAR response (\( p=0.572 \)), CRP (\( p=0.123 \)), EVA pain (\( p=0.23 \)), HAQ(\( p=0.533 \)).

**Discussion:**

Rheumatoid arthritis is a common disease which touches 0.7% of the population (about 200,000 patients in Morocco). It mainly affects women, no matter the ethnic group or the country they come from, with an average sex ratio of 3 women per man. In our research, male rheumatoid arthritis treated with biotherapy represents 12.4% (versus 87.6% of female rheumatoid arthritis), i.e. less than one eighth of all RA treated with biotherapy, making a sex ratio of 7 women per man. A Latin American study by Barragán-Martínez et al, discovered a sex ratio of 5.2 females per male and a prevalence of male RA of 16.1% among 1128 rheumatoid arthritis patients [9]. This
A statistical difference can be explained by the specificities of each study. Our study, which focused solely on patients with rheumatoid arthritis undergoing biological treatment, found a lower presence of rheumatoid arthritis than that found by the authors of the Latin American study [9]. This result can be explained by the fact that women have more severe RA and a high risk of being treated with biotherapy.

The RA characteristics also appear to be influenced by gender. In our study, female RA undergoing biologic treatments were younger than males (51 years old versus 55.96 years old), with a shorter period of time to positive diagnosis in males (562.61 weeks versus 767.19 weeks). On the one hand, our findings are consistent with those of Voulgari et al. [10] including 454 RA patients, and show a significantly higher mean age of male patients than female ones (55 years old versus 49 years old, p=0.0003).

On the one hand, the diagnostic period was reduced for men (0.3 an vs 0.6 an) in a non-statistically significant way. In the same vein, Barragán-Martínez et al. found that women with RA are younger than men (38.07 years old vs. 42.99 years old; P=0.0001) without specifying the type of treatment these patients undergo. The younger age of RA female compared to RA male is strongly influenced by the role of endocrine factors and the involvement of sexual hormones. This becomes more frequent in the time period between puberty and menopause. Men are rarely affected at a young age, so androgens seem to remove the disease. EVA pain and fatigue, joint index, swollen joint index are slightly higher in men than women. All these characteristics are not statistically significant, therefore gender does not have a greater influence on the clinical presentation of RA. The rheumatoid arthritis severity can be assessed on the presence of an inflammatory syndrome, positive rheumatoid serology, the extent of joint damage observed on X-ray images, Doppler activity on ultrasound of synovitis and erosions, the extent of functional disability, smoking, or the occurrence of extra-articular manifestations. There is a 2% difference in the positivity of rheumatoid serology (rheumatoid factor and ACPA) between men and women. This difference in our study could be explained by:

1. The high consumption of tobacco by men (10.7% versus 0.5% of female RA (p=0.006)); known to be associated with rheumatoid factor production and citrullination.
2. The inflammatory syndrome is high for men,
3. The disease activity is high (DAS28) for men.

However, HAQ, comorbidities, and radiological abnormalities are more prevalent in female RA.

Several studies have come up with the same finding [9,12]. That is to say, despite having an inflammatory syndrome and a positive rheumatoid serology, men had a lower risk of severe joint abnormality than women. In the same vein, Tuulikki Sokka, in his study the QUEST-RA [11], pinpointed at the importance and frequency of erosions in female RA (64.3% versus 59.7%, p=0.003). This paradox between the importance of the inflammatory syndrome in men and the decreased joint destruction in male RA appears to be related to the longer duration of the disease evolution. As is explained in our study, it was 768 weeks for women and 542 weeks for men. In contrast, Weyand et al. [12] found erosive RA early and more frequently in men. The same results were also found by Maarten Boers [13] with the same smoking patterns in both sexes.

Based on these data, the QUEST-RA study indicates that measures of disease activity are higher in women than men for DAS28, EVA fatigue, and number of swollen joints. Thus, this study suggests that caution must be taken into consideration when interpreting the level of disease activity since sex interferes. As reported Misbah Vaqar Patoli, the severity of rheumatoid arthritis in both sexes is variable and age-dependent as reported [14]. The influence of gender on RA characteristics differs from one study to another. In our study, male sex had a minor impact on the presentation of RA, but this influence was not statistically significant.

The period between positive diagnosis and the starting of biologic treatment is reduced for men compared to women diagnosed with RA. This short time period, in our study, is due to either disease severity, significant inflammatory syndrome and high disease activity in men compared to women, (Table 1) or resistance to conventional DMARDS therapy. According to the Dutch report, women were referred late after the onset of symptoms to specialized arthritis clinics compared to men, and consequently there was a long period of time between the appearance of symptoms and the introduction of substantive treatment [15]. In our study, male RA was not statistically related to response to biologic therapies on either the primary criteria (DAS28vs disease activity) or secondary criteria (EULAR response, biological inflammatory syndrome, EVA pain). Consequently, gender does not have an impact on the response to
biological treatment. These results are in line with those found in the literature, particularly in the European studies and the Latin American study where 28.7% of women were under biologic treatment versus 27.1% of men (115).

The RA chronic inflammation is not only limited to the joints, but also affects other organs. In this respect, the prevalence of comorbidities can be altered by the gender of the patients. In our analysis; at inclusion; comorbidities (diabetes, hypertension, obesity, hypercholesterolemia, depression, osteoporosis.) affected women more than men (Table 2). On the other hand, the presence or occurrence of pulmonary tuberculosis is more frequent in male RA (\(p=0.023\)). At 12 months on biologic treatment, the appearance of comorbidities was still more frequent in women than in men, but not statistically significant (\(p=0.144\)). Two studies by DA Silva [16] in 1992 and Burmester [17] in 2007 found a direct association between the occurrence of severe infection and early mortality in male RA.

With regard to the psychosocial impact, one must be aware of the socio-economic profile of RA patients, especially after the advent of expensive biological treatments. At the time of inclusion, the majority of patients were married, and the divorce rate was the same for both sexes. Professional occupation (manual work, trade...) was statistically related to male RA (\(p=0.000\)). Rkain et al [18] found that 42.5% of female RA patients experienced various aspects of abuse from their husbands. Divorce was statistically related to the following parameters: the young age of the patients and the low number of children. Work withdrawal was related to gender: men stopped working more frequently than women (90.9 vs. 52.2%; \(p = 0.02\)); age: subjects who stopped working were older than those who were working (48 vs. 41 years old; \(p = 0.04\)) and to the nature of work, citing patients who were working in a labour-intensive occupation (100 vs. 29.4%; \(p < 0.001\)) and patients doing manual work (75 vs. 16.7%; \(p = 0.01\)).

### Tableau 1:-- socio-demographic description of the RA population under biotherapy included in the Rbsmr.

|                          | Men (n=28) | Female(n=196) | \(P\) value |
|--------------------------|-----------|---------------|-------------|
| Age(years)               | 55,96±9   | 51,37±11      | 0.344       |
| Educational level        | 35.7% primary study | 48.2% illiterate. | 0.003 |
|                          | 32.1% secondary study | 21.8% secondary study |
|                          | 14.3% illiterate | 16.2% primary study |
|                          | 17.9% high education | 8.6% high education |
|                          |            | 5.1% unknown  |
| Marital status           | 85.72% Married | 70.1% Married | 0.372       |
|                          | 7.14% single | 13.2% single  |
|                          | 7.14% divorced | 7.1% divorced |
|                          |            | 9.1% widow    |
|                          |            | 0.5% NSP      |
| Type of healthinsurance  | 50.0% FAR, | 43.1% RAMED,  | 0.339       |
|                          | 42.9% Ramed | 30.5% FAR     |
| Profession               | 35.7% officiel | 83.2% housewife. | 0.00    |
|                          | 60.0% liberal. |               |

FAR : royal army forces, PR : Rheumatoid arthritis, RAMED : medicale assistance. NSP: no response.

### Table 2:-- clinical, biological and radiological characteristics of RA patients undergoing biotherapy (RBSMR) according to gender

|                          | Men (n=28) | Female (n=196) | \(P\) value |
|--------------------------|-----------|---------------|-------------|
| Average duration of PR evolution | 542 weeks | 768 weeks     | 0.01        |
| Diagnostic delay         | 562,61 weeks | 767,19 weeks | 0.534       |
| Time between the start of biotherapy and dg | 304 weeks | 714 weeks     | 0.021       |
| Nombre d’articulation gonflé moyen (introduction biologique) | 9.5 | 7.5 | 0.715 |
| Tabac                    | 10.7%     | 0.5%          | 0.006       |
| IA: articular index      | 16        | 13            | 0.363       |
| ESR (biological introduction) | 52.6  | 40.6          | 0.042       |
| CRP (biological introduction) | 33.4  | 28.6          | 0.565       |
### Table 1: Biological and Demographic Characteristics

| Metric                              | Mean | Standard Deviation |
|-------------------------------------|------|--------------------|
| EVA pain (biological introduction)  | 7    | 6.73               |
| EVA weariness (biological introduction) | 6.3  | 6.4                |
| BMI                                 | 25.6 | 27.86              |
| DAS CRP (biological introduction)   | 4.06 | 3.51               |
| HAQ                                 | 1.17 | 1.23               |
| Radiological destruction            | 90.5%| 92.8%              |
| Comorbidities:                      |      |                    |
| pulmonary TB                        | 28.6%| 36.0%              |
| Fibromyalgia                        | 21.4%| 7.4%               |
| Depression                          | 7.1% | 1.1%               |
| Heart disease                       | 7.1% | 1.3%               |
| Hypercholesteremia                  | 7.1% | 3.1%               |
| ESR                                 | 21.4%| 17.9%              |
| HAQ                                 | 7.1% | 17.9%              |
| Vasculitis                          | 17.9%| 17.9%              |
| Cancer                              | 7.1% | 17.9%              |
| Osteoporosis                        | 3.6% | 7.6%               |
| Past of RA surgical                 | 3.6% | 7.1%               |
| Rheumatoid serology positive (RF et ou AC anti CCP) | 96.4% | 94.1% |

**RA**: rheumatoid arthritis, **FR**: rheumatoid factor, **HTA**: arterial hypertension, **TB**: tuberculosis, **HAQ**: health assessment questionnaire, **DAS**: disease activity score, **BMI**: body mass index. **EVA**: visual analog scale, **ESR**: Erythrocyt sedimentation rate.

**Figure 1**: Comparison between the response to biological treatment as a function of sex at 6 months and 12 months from inclusion RBSMR STUDY.

**Conclusion**: 12.4% represents the prevalence of male rheumatoid arthritis in the RBSMR study including RA patients on biotherap. This study did not show significant gender differences in clinical presentation, disease activity, disease

---

**Table 2: Comorbidities**

| Disease                             | Men Percentage | Women Percentage |
|-------------------------------------|----------------|------------------|
| Pulmonary TB                        | 28.6%          | 36.0%            |
| Fibromyalgia                        | 21.4%          | 7.4%             |
| Depression                          | 7.1%           | 1.1%             |
| Heart disease                       | 7.1%           | 1.3%             |
| Hypercholesteremia                  | 7.1%           | 3.1%             |
| ESR                                 | 17.9%          | 17.9%            |
| HAQ                                 | 7.1%           | 3.1%             |
| Vasculitis                          | 17.9%          | 17.9%            |
| Cancer                              | 7.1%           | 17.9%            |
| Osteoporosis                        | 3.6%           | 7.6%             |
| Past of RA surgical                 | 3.6%           | 7.1%             |
| Rheumatoid serology positive (RF et ou AC anti CCP) | 96.4% | 94.1% |

**Figure 2**: Comparison between the response to biological treatment as a function of sex at 6 months and 12 months from inclusion RBSMR STUDY.

**Conclusion**: 12.4% represents the prevalence of male rheumatoid arthritis in the RBSMR study including RA patients on biotherap. This study did not show significant gender differences in clinical presentation, disease activity, disease activity score.
severity, rheumatoid serology and response to biologic treatments after one year. In contrast, male RA was associated with smoking, occupation, and history or occurrence of pulmonary tuberculosis.

Declaration of links of interest
The authors declare that they have no links of interest.

Acknowledgements:
The authors would like to thank the scientific Committee and national principal investigators of the RBSMR study: Lahcen Achemlal, FadouaAllali, Rachid Bahiri, Imane El Bouchti, Imad El Ghoulzani, Abellah El Maghraoui, Toufik Harzy, Ihsane Hmamouchi, Linda Ichchou, Ouafa Mkinsi, Redouane Niamane and Hasnah Assikou; patients who agreed to participate in this study.

Funding
Data collection was supported by an unrestricted grant from Pfizer, Novartis, Janssen, and Abbvie. The ancillary study described in this manuscript was done without any type of funding.

Ethics approval
The protocol for the original RBSMR study was reviewed and approved by local institutional review boards and the national ethic committee.

Référence:--
1. Jawaheer D, Lum RF, Gregersen PK, Criswell LA. Influence of male sex on disease phenotype in familial rheumatoid arthritis. Arthritis Rheum. 2006;54:3087-3094.
2. Forslind K, Hafstrom I, Ahlmen M, Svensson B. Sex: A major predictor of remission in early rheumatoid arthritis? Ann Rheum Dis. 2007;66:46-52.
3. Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, et al. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: The GISEA study. J Rheumatol. 2007;34:1670-1673.
4. Hyrich KL, Watson KD, Silman AJ, Symmons DP. British Society for Rheumatology Biologics Register. Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2006;45:1558-1565.
5. Yamanaka H, Tanaka Y, Sekiguchi N, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol. 2007;17:28-32.
6. Kvien TK, Uhlig T, Odegard S, Heiberg MS. Epidemiological aspects of rheumatoid arthritis: The sex ratio. Ann N Y Acad Sci. 2006;1069:212-222.
7. Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. AutoimmunRev2005;4:130-6.
8. Drosos AA. Epidemiology of rheumatoid arthritis. Autoimmun Rev 2004;3 Suppl 1:S20-2.
9. Barragán-Martínez C, Amaya-Amaya J, Pineda-Tamayo R, Mantilla R D, ... Juan- Anaya M. Gender Differences in Latin-American Patients With Rheumatoid Arthritis;Gender Medicine. December 2012, Pages 490-510.e5
10. Voulgari P.V1, Papadopoulos LA1, Alamanos Y2, Katsaraki A1, Drosos AA1. Early rheumatoid arthritis: Does gender influence disease expression?. Clinical and Experimental Rheumatology 2004; 22: 165-170.
11. Sokka T, Tooloza S, Cutolo M, Kautiainen H, Makinen H, Gogus F, Géher P (2009). Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis research & therapy, 11(1), R7.
12. Weyand CM, Schmidt D, Wagner U, Goronzky JJ (1998). The influence of sex on the phenotype of rheumatoid arthritis. Arthritis & Rheumatology, 41(5), 817-822.*
13. Maarten Boers. Department of Clinical Epidemiology. Vrije Universiteit University Hospital, THE LANCET • Vol 352 • August 8, 1998
14. Patoli MV 3*, Fasilha S2*, Sumner N, Zakir MF1*, et Al. Don't Judge Disability with its Visibility: Gender Variation in Frequency of Rheumatoid Arthritis with its Clinical Parameters. Merit Research Journal of Medicine and Medical Sciences (ISSN: 2354-323X) Vol. 6(8) pp. 278-283, August, 2018.
15. Lard LR, Visser H, Speyer I, Horst-Bruinsma IE vander, Zwinderman AH, Breedveld FC, Hazes JMW: Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001, 111:446-451
16. Da Silva JAP, Hall GM (1992). The effects of gender and sex hormones on outcome in rheumatoid arthritis. Baillière's clinical rheumatology, 6(1), 193-219.
17. Burmester GR, Mariette X, Montecucco C, Monteagudo-Sáez I, Malaise M, Tzioufas AG, Kupper H (2007). Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Annals of the rheumatic diseases, 66(6), 732-739.
18. Rkain H', Allali F, Jroundi I, Hajjaj-Hassouni N. Socioeconomic impact of rheumatoid arthritis in Morocco. Joint Bone Spine. 2006 May;73(3):278-83. Epub 2005 Nov 4.